Jazz Stock Hits New 52-Week High (JAZZ)

NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Wednesday as it traded at $29.78 compared with its previous 52-Week high of $29.73. Jazz is changing hands at $29.62 with 295,816 shares traded as of 10:36 a.m. ET. Average volume has been 699,300 shares over the past 30 days.

Jazz has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 47.3% year to date as of the close of trading on Tuesday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company has a P/E ratio of 34.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.

TheStreet Ratings rates Jazz as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including premium valuation and generally poor debt management. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins